Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study
Background Limited research exists on the features and management of post-COVID cough. This real-world study investigates outpatients with subacute or chronic post-COVID cough, aiming to delineate characteristics and regimen responses within the population. Method We enrolled eligible patients from...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2024-12-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/18705.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846124661382840320 |
|---|---|
| author | Chun Yao Dongliang Cheng Wenhong Yang Yun Guo Tong Zhou |
| author_facet | Chun Yao Dongliang Cheng Wenhong Yang Yun Guo Tong Zhou |
| author_sort | Chun Yao |
| collection | DOAJ |
| description | Background Limited research exists on the features and management of post-COVID cough. This real-world study investigates outpatients with subacute or chronic post-COVID cough, aiming to delineate characteristics and regimen responses within the population. Method We enrolled eligible patients from our outpatient unit between August 2023 and February 2024. Comprehensive clinical data, prescriptions, and patient-reported cough severity were collected during the primary visit and subsequent follow-ups. Result A total of 141 patients, aged: 42 ± 14 years old, were included, with 70% being female. The median cough duration was 8 weeks (interquartile range 4–12 weeks). Sixty percent presented with a dry cough, while the rest had coughs with phlegm. Over half reported abnormal laryngeal sensations (54%). Twenty-one percent coughed during the day, while 32% coughed constantly, and 48% experienced nocturnal episodes. Compound methoxyphenamine capsules were the most prescribed, but our study found ICS/LABA to be the most effective, followed by compound methoxyphenamine capsules, montelukast, and Chinese patent drugs. Conclusion Females exhibit a higher prevalence of post-COVID cough, and our study recommends ICS/LABA as the preferred treatment. These findings warrant validation through larger, prospectively designed studies. |
| format | Article |
| id | doaj-art-837f53f6b2364c4ab38f25d3da76319b |
| institution | Kabale University |
| issn | 2167-8359 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj-art-837f53f6b2364c4ab38f25d3da76319b2024-12-13T15:05:13ZengPeerJ Inc.PeerJ2167-83592024-12-0112e1870510.7717/peerj.18705Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world studyChun YaoDongliang ChengWenhong YangYun GuoTong ZhouBackground Limited research exists on the features and management of post-COVID cough. This real-world study investigates outpatients with subacute or chronic post-COVID cough, aiming to delineate characteristics and regimen responses within the population. Method We enrolled eligible patients from our outpatient unit between August 2023 and February 2024. Comprehensive clinical data, prescriptions, and patient-reported cough severity were collected during the primary visit and subsequent follow-ups. Result A total of 141 patients, aged: 42 ± 14 years old, were included, with 70% being female. The median cough duration was 8 weeks (interquartile range 4–12 weeks). Sixty percent presented with a dry cough, while the rest had coughs with phlegm. Over half reported abnormal laryngeal sensations (54%). Twenty-one percent coughed during the day, while 32% coughed constantly, and 48% experienced nocturnal episodes. Compound methoxyphenamine capsules were the most prescribed, but our study found ICS/LABA to be the most effective, followed by compound methoxyphenamine capsules, montelukast, and Chinese patent drugs. Conclusion Females exhibit a higher prevalence of post-COVID cough, and our study recommends ICS/LABA as the preferred treatment. These findings warrant validation through larger, prospectively designed studies.https://peerj.com/articles/18705.pdfCOVID-19CoughRegimensReal-world studyOutpatients |
| spellingShingle | Chun Yao Dongliang Cheng Wenhong Yang Yun Guo Tong Zhou Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study PeerJ COVID-19 Cough Regimens Real-world study Outpatients |
| title | Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study |
| title_full | Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study |
| title_fullStr | Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study |
| title_full_unstemmed | Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study |
| title_short | Characterization and clinical outcomes of outpatients with subacute or chronic post COVID-19 cough: a real-world study |
| title_sort | characterization and clinical outcomes of outpatients with subacute or chronic post covid 19 cough a real world study |
| topic | COVID-19 Cough Regimens Real-world study Outpatients |
| url | https://peerj.com/articles/18705.pdf |
| work_keys_str_mv | AT chunyao characterizationandclinicaloutcomesofoutpatientswithsubacuteorchronicpostcovid19cougharealworldstudy AT dongliangcheng characterizationandclinicaloutcomesofoutpatientswithsubacuteorchronicpostcovid19cougharealworldstudy AT wenhongyang characterizationandclinicaloutcomesofoutpatientswithsubacuteorchronicpostcovid19cougharealworldstudy AT yunguo characterizationandclinicaloutcomesofoutpatientswithsubacuteorchronicpostcovid19cougharealworldstudy AT tongzhou characterizationandclinicaloutcomesofoutpatientswithsubacuteorchronicpostcovid19cougharealworldstudy |